Zymeworks ticks all the boxes for a biopharma investment, Paradigm says

Mar 05 22:03 2020 Print This Article

Zymeworks (Zymeworks Stock Quote, Chart, News NYSE:ZYME) has what investors should be looking for in a biopharmaceutical company, according to Paradigm Capital analyst Corey Hammill, namely, a strong balance sheet and a healthy-looking pipeline. The analyst reviewed Zymeworks latest quarterly results in an update to clients on Tuesday and reiterated his “Buy” rating and 12-month […]

The post Zymeworks ticks all the boxes for a biopharma investment, Paradigm says appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

  Categories:

Related Items

Question and Answer session on The Citizen’s Guide to Climate Success

Here is the video recording of my Question and Answer session on The Citizen’s Guide to Climate Success on May 12, 2020. Thank you to the group, Climate Crisis Legislation Needed Now, particularly Ken Johnson and Kathleen O’Hara. ...

The state of COVID-19 testing

In these unprecedented times, we know that controlling the spread of novel coronavirus requires social distancing and testing. While all of us are doing our parts to stay at home, there’s a lot of confusion, chaos and frustration surrounding coronavirus testing in the US.  Before going further, ...

Thoughts on the State of DeFi

The last couple of weeks have been quite a test for cryptocurrency markets in general and DeFi in particular. On Black Thursday (March 12), BTC/ETH prices declined by ~50% and DeFi’s flagship project, MakerDAO, ended up with ~$5 million USD in unbacked DAI. You can read Tom Schmidt’s excellent ...

Is this the crypto inflection point we’ve been waiting for? 

If you spend a lot of time in crypto (like we do here at V1), it can be easy to lose sight of how non-crypto investors and entrepreneurs think about the space. The huge ICO run-up in 2017 brought a lot of attention to the vertical. Since then, many have stopped following the progress or have become ...

B2B Marketplaces Revisited

Twenty years ago – in the midst of the Web 1.0 boom – expectations were high for B2B (product) marketplaces. The assumption was that online platforms would completely automate all supplier-customer transactions including retailing, wholesaling, and procurement. Yet today, the world of B2B marke ...

Zymeworks ticks all the boxes for a biopharma investment, Paradigm says

Zymeworks (Zymeworks Stock Quote, Chart, News NYSE:ZYME) has what investors should be looking for in a biopharmaceutical company, according to Paradigm Capital analyst Corey Hammill, namely, a strong balance sheet and a healthy-looking pipeline. The analyst reviewed Zymeworks latest quarterly resul ...

Q4 2019 Share Price Performance

Q4 2019 Share Price Performance Healthcare Stocks Surge  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2019, and provides commentary on select stock movements and overall market trends.  Inclusion Criteria  Our ana ...

IMV gets price target cut from Raymond James

New clinical results from biopharm company IMV (IMV Stock Quote, Chart, News TSX:IMV) signal a less straightforward path to commercialization than previously assumed, according to Raymond James analyst David Novak, who reviewed the results in an update to clients on Wednesday. Dartmouth, Nova Scoti ...

Yikes to the Year End!

Originally published in December 2019 Clearly, there is more going on these days in Washington, D.C. than just the impeachment hearings, and activities this week made that point clear. In the span of only a few days, we saw progress on two key issues – the China 301 tariffs and the U.S.-Mexico-Ca ...

China – U.S. Phase 1 Deal – Means What?

Originally published in the Journal of Commerce in January 2020 As has been widely publicized, China and the U.S. signed the so-called Phase 1 deal on January 15, 2020. The agreement runs 90+ pages, the text of which can be found here: Phase 1 Deal.pdf.  The supporting U.S. Trade Representative (U ...